- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02308904
Reproductive Capacity and Iron Burden in Thalassemia (Fertility thal)
Reproductive Capacity and Association to Iron Burden and Chelation Patterns in Thalassemia Major Patients
The improved long-term survival of thalassemia major (TM) patients has resulted in increased focus on the ability to preserve fertility. While the association of iron toxicity with vital organ dysfunction, heart and liver, has been extensively investigated, the correlation of reproductive capacity and extent of iron overload is not well understood. Despite remarkable progress in methodology for prediction of reproductive status and intervention for preserving fertility, implementation in thalassemia is lacking.
The investigators hypothesize that iron toxicity to the anterior pituitary occurring in the process of transfusional iron loading is directly associated with a decline in gonadal function. The investigators expect pituitary MRI measurements of iron deposition as well as markers of oxidative damage to correlate with the functional studies of pituitary-gonadal axis performed in this study. This cross sectional study will examine the relation of pituitary iron deposition and pituitary volume; serum iron and oxidative stress measures, liver iron concentration (LIC), cardiac iron and chelation adequacy with pituitary and gonadal reproductive hormone levels (and spermatogenesis in adult male patients), in order to better define the association of iron burden and chelation patterns with fertility potential, in thalassemia patients with iron overload. The study will assess whether the current chelation treatment regimens, in particular during the pubertal developmental age, are adequate for preserving fertility and could lead to improved chelation routines for preventing the high prevalence of compromised fertility. In addition, by utilizing state-of-the-art markers for fertility status, findings from this study may improve current methods for screening for hypogonadism and reproductive potential and allow earlier intervention.
The investigators propose to examine 26-30 patients, 12 years and older, with measures of fertility potential, and correlate them to their current iron burden parameters and to the cumulative iron effect as indicated by past iron overload patterns and chelation history.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Oakland, California, United States, 94609
- UCSF Benioff Children's Hospital Oakland
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Transfusion-dependent* females and males with thalassemia (any genotype) who are 12 to 45 years of age.
- History of at least 5 years of chronic transfusion (defined as ≥ 8 transfusions/year) (Age of initiation of transfusions does not matter)
- Any pubertal stage.
- Liver iron evaluated by SQUID, MRI or liver biopsy within 12 months prior to enrollment in the study.
- Need to be able to stop hormonal therapy for 3 weeks (males) and one month (females) prior to study enrollment.
Exclusion Criteria:
- Pregnant or lactating during study enrollment
- Unable to obtain liver iron concentration within 12 months prior or 6 months after study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Laboratory Studies for Pituitary-Gonadal Function
Females: We expect to enroll approximately 15 females ages 12 years and older. Males: We expect to enroll approximately 15 males ages 12 years and older. |
Females: 1. Obtain levels of LH/FSH, Estradiol, and AMH in all enrolled women. Males: We expect to enroll approximately 15 males ages 12 years and older.
Other Names:
|
Other: Data on iron burden and chelation history
Retrospective data, as listed in this section, will be obtained from chart review and results of relevant clinical data.
|
|
Other: Pituitary MRI
MRI has been shown to demonstrate well the changes related to iron toxicity in the pituitary gland.
|
MRI has been shown to demonstrate well the changes related to iron toxicity in the pituitary gland. An MRI protocol was optimized at Children's Hospital and Research Center Oakland (CHRCO) and Texas Children's Hospital. Utilizing 1.5 T clinical scanner to evaluate the iron accumulation in the anterior pituitary. The total data acquisition time is approximately 32 minutes. No sedation will be given. MRI data will be sent to Dr. Wang, department of Radiology, Children's Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas. Quantification of R2, pituitary height and volume will be conducted. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Laboratory studies for pituitary and gonadal function and for iron level measures
Time Frame: Up to 12 months
|
Each patient's pituitary iron and pituitary volume will be correlated with each hormone levels: LH, FSH, estrogen and AMH (Females), testosterone Inhibin B and (males). We will then evaluate potential associations using Pearson correlations. Univariate analyses on all variables and it's relation with iron, will also be conducted. |
Up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Retrospective analysis of annual LIC and of type and dose of iron chelation agent in the parallel time period
Time Frame: Up to 12 months
|
We will evaluate potential associations using Pearson correlations of each measure: Mean LIC with each of the fertility hormone levels and with pituitary volume and height.
Mean ferritin with each of the fertility hormone levels and with pituitary volume and height.
NTBI with each of the fertility hormone levels and with pituitary volume and height.
Oxidative measures (Vit C, Vit E, GSH/GSSG) with each of the fertility hormone levels and with pituitary volume and height.
Regression analysis will be utilized to assess correlation of pituitary iron, LIC and cardiac iron.
We will compute descriptive statistics for all measures by group.
We will assess differences between the 2 groups using Student's t-test for continuous data and chi-square or Fisher's exact for categorical.
A detailed retrospective analysis of LIC and chelation patterns (type of chelator and average dose) on these 2 groups will also be performed and fertility measures will be compared.
|
Up to 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pituitary MRI and Male: Semen analysis
Time Frame: Up to 12 months
|
Pituitary iron and pituitary volume will be correlated with sperm count and with DNA breakage in males (≥18 years old) who have these test results.
Statistical methods as detailed under primary objective, will be utilized.
|
Up to 12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Sylvia T Singer, MD, UCSF Benioff Children's Hospital Oakland
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CICL670AUS46T
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on THALASSEMIA MAJOR
-
University of California, San FranciscoRecruitingAlpha-Thalassemia | Alpha Thalassemia Major | Alpha Thalassemia MinorUnited States
-
BGI-researchShenzhen Children's HospitalNot yet recruiting
-
CorrectSequence Therapeutics Co., LtdNot yet recruitingBeta-Thalassemia MajorChina
-
First Affiliated Hospital of Guangxi Medical UniversityUnknown
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingConfirmed Diagnosis of ß-thalassemia MajorUnited States
-
Aghia Sophia Children's Hospital of AthensUnknownAsplenia | β-thalassemia MajorGreece
-
bluebird bioCompletedSickle Cell Disease | Beta-Thalassemia MajorFrance
-
University of California, San FranciscoCalifornia Institute for Regenerative Medicine (CIRM)Enrolling by invitationHemoglobinopathies | Alpha Thalassemia Major | Thalassemia Major | Fetal Hydrops | Hemoglobinopathy; With Thalassemia | Fetal Anemia | Alpha; Thalassemia | Thalassemia Alpha | A-ThalassemiaUnited States
-
Editas Medicine, Inc.RecruitingHemoglobinopathies | Thalassemia Major | Thalassemia Intermedia | Transfusion Dependent Beta ThalassemiaUnited States, Canada
-
Isfahan University of Medical SciencesMadaus IncUnknownIron Overload | Beta-thalassemia MajorIran, Islamic Republic of
Clinical Trials on Blood Draw/Semen Exam
-
Memorial Sloan Kettering Cancer CenterCompletedBreast Cancer | Long-Term SurvivorsUnited States
-
Memorial Sloan Kettering Cancer CenterYale University; University of New MexicoCompleted
-
University of California, San DiegoLivivos, Inc.Recruiting
-
University Hospital, ToulouseCompleted
-
Abbott Point of CareNot yet recruitingPrecision of Potassium (K) Test in Capillary Whole Blood
-
University Hospital, Strasbourg, FranceNot yet recruitingKidney Transplantation | Humoral Rejection | Kidney Allograft Biopsy | Microvascular Inflammation
-
University of ZurichCompleted
-
University Hospital, ToulouseCompleted
-
Vanderbilt-Ingram Cancer CenterWren Laboratories LLCCompletedMelanomaUnited States